AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well AZD2171 works in treating patients with relapsed or
refractory B-cell chronic lymphocytic leukemia. AZD2171 may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth and by blocking blood flow to the
cancer cells